We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGORX - GeoPharma, Inc.

From: jmhollen8/3/2005 5:22:09 PM
   of 7
News and PRs for GeoPharma, Inc.:

Date -------------------- Story -------------------- Source

07:55 GeoPharma Announces First Quarterly Earnings Conference Call (Full Story) PR Newswire

17:47 Corporate Announcement: GeoPharma Inc (Full Story) Wall Street Horizon

07:55 GeoPharma Reports 22% Revenue Increase for the Year (Full Story) PR Newswire

17:48 Corporate Announcement: GeoPharma Inc (Full Story) Wall Street Horizon

14:03 GeoPharma Announces Year End Conference Call (Full Story) PR Newswire


Share RecommendKeepReplyMark as Last Read

From: jmhollen8/3/2005 5:23:30 PM
   of 7
GeoPharma Announces First Quarterly Earnings Conference Call

LARGO, Fla., July 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- GeoPharma, Inc. (Nasdaq: GORX), will hold its quarterly conference call to discuss June 30, 2005 quarterly results on Wednesday, August 3, 2005, at 11:00 a.m. (ET). Participants can call in on Wednesday, August 3, 2005 at 10:55 a.m. at 1-800-265-0241, passcode 33189768.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at , Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ( ), a password-protected event management site.

About GeoPharma, Inc.

GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche human and animal health markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at , and .

SOURCE GeoPharma, Inc.
Carol Dore-Falcone, GeoPharma, Inc., +1-727-544-8866

Share RecommendKeepReplyMark as Last Read

From: ThinkingBig8/16/2005 9:57:47 AM
   of 7
GeoPharma Acquires Controlling Interest in Antibiotic Manufacturing Facility
Expands to Beta-Lactam and Penicillin-based Antibiotics
8/16/2005 8:01:13 AM

LARGO, Fla., Aug 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- GeoPharma, Inc. (GORX) announced today that, through a newly-formed subsidiary, it has acquired substantially all of the assets of Consolidated Pharmaceutical Group, Inc., an antibiotic manufacturer located in Baltimore, Maryland. The acquisition was made through American Antibiotics LLC, a newly-formed Florida limited liability company. GeoPharma has the controlling interest in American Antibiotics.

"We are very pleased to become one of a few penicillin-based manufacturers in North America. The ability to manufacture beta-lactam antibiotics in Baltimore, coupled with production of Cephlasporin-based antibiotics through our plant in Florida, will allow GeoPharma to provide a full range of antibiotics to the market," said GeoPharma Chief Executive Officer, Mihir Taneja.
Consolidated Pharmaceuticals manufactures sterile and non-sterile beta-lactam and penicillin-based antibiotics in solid dosage and injectable form. These assets acquired by American Antibiotics consist of five ANDA (Abbreviated New Drug Applications) with 10 dosage strengths and relevant intellectual property for manufacturing these items.

Prior to 2000, Consolidated Pharmaceuticals had manufactured antibiotics under its own label in addition to other well-known pharmaceutical labels. GeoPharma will revitalize and upgrade the Consolidated Pharmaceuticals facility to ensure compliance with the current regulatory standards of the U.S. Food and Drug Administration (FDA).

Commercial production is expected to commence during the second quarter of 2006. American Antibiotics will begin production with the five ANDAs in 10 dosage forms: Amoxicillin 250mg and 500mg oral capsule, Amoxicillin 125mg / 5ml and 250mg / 5ml suspensions, Ampicillin 250mg and 500mg oral capsule, Ampicillin 125mg / 5ml and 250mg / 5ml suspensions, and Penicillin V. Potassium 125mg / 5ml and 250mg / 5ml suspension.

According to NDCHealth, a leading provider of healthcare technology and information, Amoxicillin is one of the most widely prescribed drugs in the United States, with more than 40 million prescriptions written annually. Amoxicillin is indicated for a broad range of infections, and is commonly prescribed as a first-line of therapy for common infections.

"We believe both groups of product will allow us to carve out a niche position in a segment dominated by few competitors," concluded Mr. Taneja.

American Antibiotics also entered into a new lease with Consolidated Pharmaceutical for its facility in Baltimore, where the manufacturing plant will continue to be operated

Share RecommendKeepReplyMark as Last Read

From: ThinkingBig10/4/2005 12:52:54 PM
   of 7
GeoPharma Announces Dismissal of Class Action Litigation Relating to Mucotrol (TM)

Tuesday October 4, 8:31 AM EDT

LARGO, Fla., Oct 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- GeoPharma, Inc. (GORX) announced today that a lawsuit alleging that the Company violated federal securities laws by issuing false or misleading public statements relating to the Company's December 1, 2004 announcement of Mucotrol's(TM) clearance by the FDA was dismissed on September 30, 2005 without prejudice by a judge in the United States District Court for the Southern District of New York. The judge did allow plaintiffs twenty days to attempt to replead their claims.

Mihir Taneja, GeoPharma's CEO commented: "We are extremely pleased by the Court's ruling, which granted our motion to dismiss the Complaint. We are aggressively moving forward with the launch of Mucotrol(TM)."

On November 24, 2004, the Food and Drug Administration (FDA) granted 510-K approval for the marketing of Mucotrol(TM) as a medical device. Mucotrol(TM) concentrated oral gel wafer has a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth and soothing oral lesions of various origins including oral mucositis/stomatitis, which may be caused by chemotherapy or radiotherapy, irritation due to oral surgery and traumatic ulcers caused by braces or ill fitting dentures or diseases.

Share RecommendKeepReplyMark as Last Read

From: ThinkingBig2/8/2006 9:43:02 AM
   of 7
On January 20, Mihir Taneja, CEO of GeoPharma, Inc. (Nasdaq: GORX - News) updated the investment community in an all-new interview with Interview highlights include detailed discussions on the following topics:

- current manufacturing capabilities, and customers

- focus on the manufacturing of generic-drugs

- industry trends, and potential for growth

- key drivers behind recent earnings surge

- competitive edge in the industry

- upcoming strategic and financial milestones

To hear the interviews in their entirety, visit , and click on "Interviews/Podcasts." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews/Podcasts" page or by entering the respective company's ticker symbol in the Search Archive window at the bottom of the "Interviews/Podcasts" page.

Share RecommendKeepReplyMark as Last Read

From: ThinkingBig8/14/2006 2:16:11 PM
   of 7
GeoPharma, Inc. Announces Interview With CEO Mihir Taneja
Monday August 14, 1:00 pm ET

LARGO, Fla., Aug. 14 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX - News), a pharmaceutical company specializing in manufacturing and distributing over-the-counter, nutritional, generic drug and functional food products, announced today that the Company's CEO, Mihir Taneja, was interviewed on August 3rd, 2006 by the Zangani Investor Community, who have been retained as the company's Investor Relations firm.

Mr. Taneja highlighted growth strategies for the future of GeoPharma, Inc. To access the interview, please visit the Zangani Investor Community at:

The interview is also available via Podcast at or through the iTunes music store.

Share RecommendKeepReplyMark as Last Read

From: ThinkingBig8/14/2006 6:33:31 PM
   of 7
GEOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon 2:29pm)

Share RecommendKeepReplyMark as Last Read